Amgen Buys Otezla
Amgen buys Otezla. Amgen buys Otezla from Celgene for $13.4 billion. The deal gives Amgen the drug Otezla and its related intellectual property. Celgene teams who make Otezla will transfer to Amgen . The drug is approved for three distinct inflammatory diseases in the US and has exclusive intellectual property rights until 2028. Otezla is approved in 54 countries, including the major markets of France, Germany, and Japan. G iovanni Caforio of Bristol-Myers said: ‘This agreement is an important step toward completing our pending merger with Celgene . It also demonstrates the tremendous achievement of the Celgene team in establishing Otezla as an important medicine for patients with psoriasis, psoriatic arthritis, and Behçet’s Disease. Together with the Otezla team, Amgen has the capabilities and infrastructure to continue to support this important medicine and ensure a seamless transition for patients and healthcare prov...